# Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2026 Canonical URL: https://biopharmsignal.com/news/FNA/zimmer-biomet-announces-quarterly-dividend-for-second-quarter-of-2026-fe05ba3b Ticker: FNA Company: Paragon 28 Source: Paragon 28 Published: 2026-07-09 00:07 EST Original Source URL: https://ir.paragon28.com/news/default.aspx ## Summary WARSAW, Ind., May 22, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2026. The cash dividend of $0.24 per share is ## Article Body , /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2026. The cash dividend of $0.24 per share is payable on or about July 31, 2026 to stockholders of record as of the close of business on June 25, 2026. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation. For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X at www.x.com/zimmerbiomet . Contacts: Media Investors Troy Kirkpatrick David DeMartino 614-284-1926 646-531-6115 [email protected] [email protected] Kirsten Fallon Zach Weiner 781-779-5561 908-591-6955 [email protected] [email protected] View original content to download multimedia: https://www.prnewswire.com/news-releases/zimmer-biomet-announces-quarterly-dividend-for-second-quarter-of-2026-302780431.html SOURCE Zimmer Biomet Holdings, Inc. ## Recent Company News - 2026-07-09 00:07 EST — [Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2026](https://biopharmsignal.com/news/FNA/zimmer-biomet-announces-quarterly-dividend-for-second-quarter-of-2026-fe05ba3b) — Source: Paragon 28 - 2026-07-09 00:07 EST — [Zimmer Biomet to Present at the Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/FNA/zimmer-biomet-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conf-0913fd4d) — Source: Paragon 28 ## Related News - 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47) - 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640) - 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0) - 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f) - 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)